文献速递血栓与止血

靶向蛋白酶nexin-1(PN-1)控制血友病出血并改善止血

Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.
PubMed 文献 · Blood · 2019-01-01

本研究提出靶向血小板表达的自然凝血酶抑制剂蛋白酶nexin-1(PN-1)的非凝血因子替代策略。在轻/中度血友病患者富血小板血浆中,PN-1中和抗体可显著缩短组织因子触发的凝血酶爆发;在胶原诱导血小板活化后,重度患者及F8-/-小鼠PN-1缺失或阻断亦显著改善凝血酶生成。F8-/-/PN-1-/-小鼠在多类出血模型中出血量与出血时间显著减少,血栓弹力检测示血凝块稳定性增强、溶解时间延长,提供PN-1中和用于血友病临床治疗的概念验证。

要点

  • PN-1中和抗体可缩短轻/中度血友病患者富血小板血浆中组织因子触发的凝血酶爆发。
  • 重度血友病患者仅在胶原诱导血小板活化后阻断PN-1才显著改善凝血酶生成。
  • F8-/-/PN-1-/-小鼠出血量及出血时间显著减少,血凝块稳定性增强、溶解时间延长。

核心结论

  • 靶向血小板来源的PN-1可改善血友病止血,提供PN-1中和作为未来临床治疗新策略的概念验证。

研究设计与样本

  • 基础与转化研究:采用校准自动凝血酶生成试验检测患者富血小板血浆,并在F8-/-小鼠及F8-/-/PN-1-/-小鼠多种出血模型中验证。

主要发现

  • 轻/中度血友病患者富血小板血浆中,PN-1中和抗体显著缩短组织因子触发的凝血酶爆发。
  • 重度血友病患者富血小板血浆中PN-1中和未改善凝血酶生成;胶原诱导血小板活化后,F8-/-小鼠PN-1缺失或重度患者PN-1阻断显著改善凝血酶生成。
  • 多种出血模型中,F8-/-/PN-1-/-小鼠较F8-/-小鼠出血量与出血时间显著减少。
  • 氯化铁诱导肠系膜血管损伤模型中,F8-/-/PN-1-/-小鼠较F8-/-小鼠血小板募集与纤维蛋白(原)蓄积显著增高。
  • 血栓弹力检测显示F8-/-/PN-1-/-小鼠及经PN-1中和抗体孵育的血友病A患者血样较各自对照血凝块稳定性增强、血凝块溶解时间延长。

临床怎么用

  • 研究为概念验证阶段,尚未提供临床用药剂量、给药方案或治疗阈值。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophilia A and B, diseases caused by the lack of factor VIII (FVIII) and factor IX (FIX) respectively, lead to insufficient thrombin production, and therefore to bleeding. New therapeutic strategies for hemophilia treatment that do not rely on clotting factor replacement, but imply the neutralization of natural anticoagulant proteins, have recently emerged. We propose an innovative approach consisting of targeting a natural and potent thrombin inhibitor, expressed by platelets, called protease nexin-1 (PN-1). By using the calibrated automated thrombin generation assay, we showed that a PN-1-neutralizing antibody could significantly shorten the thrombin burst in response to tissue factor in platelet-rich plasma (PRP) from patients with mild or moderate hemophilia. In contrast, in PRP from patients with severe hemophilia, PN-1 neutralization did not improve thrombin generation. However, after collagen-induced platelet activation, PN-1 deficiency in F8-/-mice or PN-1 blocking in patients with severe disease led to a significantly improved thrombin production in PRP, underlining the regulatory role of PN-1 released from platelet granules. In various bleeding models, F8-/-/PN-1-/- mice displayed significantly reduced blood loss and bleeding time compared with F8-/-mice. Moreover, platelet recruitment and fibrin(ogen) accumulation were significantly higher in F8-/-/PN-1-/- mice than in F8-/-mice in the ferric chloride-induced mesenteric vessel injury model. Thromboelastometry studies showed enhanced clot stability and lengthened clot lysis time in blood from F8-/-/PN-1-/- and from patients with hemophilia A incubated with a PN-1-neutralizing antibody compared with their respective controls. Our study thus provides proof of concept that PN-1 neutralization can be a novel approach for future clinical care in hemophilia.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Aymonnier K, Kawecki C, Venisse L, et al. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia. Blood. 2019. PMID: 31383642. doi:10.1182/blood.2019000281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。